Privia Health Q3 Revenue Rises 32.5%, Raises 2025 Revenue and EBITDA Guidance
Privia Health reported third-quarter 2025 revenue of $580.4 million, up 32.5% from a year earlier, and net income attributable to the company of $6.9 million, up from $3.5 million. The company raised its full-year 2025 outlook, including GAAP revenue guidance of $2.05 billion to $2.1 billion and Adjusted EBITDA guidance of $118 million to $121 million, both above prior ranges.
Key points
- Q3 2025 total revenue was $580.4 million, up 32.5% from $437.9 million in Q3 2024.
- Net income attributable to Privia Health Group was $6.9 million, or $0.05 per diluted share, versus $3.5 million, or $0.03, a year earlier.
- Updated FY2025 guidance: GAAP revenue $2.05 billion to $2.1 billion (previously $1.8 billion to $1.9 billion); Adjusted EBITDA $118 million to $121 million (previously $105 million to $110 million).
- Pending acquisition of Evolent Health's ACO business for $100 million in cash plus up to $13 million more, expected to close in Q4 2025; the company had $441.4 million in cash and no debt at September 30, 2025.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:49 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.